Runben Biotechnology (SH:603193) Hua Yuan Zheng Quan·2025-08-20 08:53Investment Rating - The investment rating for the company is "Buy" (maintained) [5] Core Views - The company is actively expanding its offline channels and is expected to see strong performance from its new youth product series [5] - The company achieved a total revenue of 895 million yuan in the first half of 2025, representing a year-on-year growth of 20.31%, and a net profit attributable to shareholders of 188 million yuan, up 4.16% year-on-year [8] - The company has launched over 40 new or upgraded products in the first half of 2025, focusing on sunscreen products for infants and youth, thereby expanding its product matrix [8] - The gross profit margin for the first half of 2025 increased by 0.4 percentage points to 59.0%, while the net profit margin decreased by 3.2 percentage points to 20.9% [8] - The company is expected to achieve net profits of 330 million yuan, 410 million yuan, and 490 million yuan from 2025 to 2027, with corresponding year-on-year growth rates of 11%, 23%, and 19% [8] Financial Summary - The company’s revenue is projected to grow from 1,318 million yuan in 2024 to 2,302 million yuan in 2027, with growth rates of 27.61%, 24.81%, 20.96%, and 15.68% respectively [7][9] - The net profit attributable to shareholders is forecasted to increase from 300 million yuan in 2024 to 488 million yuan in 2027, with growth rates of 32.80%, 11.13%, 22.61%, and 19.42% respectively [7][9] - The company’s return on equity (ROE) is expected to rise from 14.43% in 2024 to 18.56% in 2027 [7][10]